These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 21339344)

  • 1. Longitudinal MR imaging in Alzheimer disease: a study anyone can join.
    Bizzi A
    Radiology; 2011 Mar; 258(3):657-9. PubMed ID: 21339344
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
    Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
    Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's biomarker initiative hits its stride.
    Miller G
    Science; 2009 Oct; 326(5951):386-9. PubMed ID: 19833956
    [No Abstract]   [Full Text] [Related]  

  • 6. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of preclinical Alzheimer's disease.
    Skoog I
    N Engl J Med; 2000 Aug; 343(7):502-3. PubMed ID: 10944568
    [No Abstract]   [Full Text] [Related]  

  • 8. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
    Sluimer JD; Bouwman FH; Vrenken H; Blankenstein MA; Barkhof F; van der Flier WM; Scheltens P
    Neurobiol Aging; 2010 May; 31(5):758-64. PubMed ID: 18692273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grey matter and cognitive patterns in cognitive impaired subjects using CSF biomarker cut-offs.
    Miralbell J; Spulber G; Hooshmand B; Besga A; Mataró M; Cedazo-Minguez A; Kivipelto M; Wahlund LO
    J Alzheimers Dis; 2012; 29(4):741-9. PubMed ID: 22330819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease.
    Kester MI; van der Flier WM; Mandic G; Blankenstein MA; Scheltens P; Muller M
    J Alzheimers Dis; 2010; 20(4):1083-90. PubMed ID: 20413898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].
    Paradowski B; Szczepaniak M; Dobosz T; Sasiadek M
    Pol Merkur Lekarski; 2000 Nov; 9(53):758-9. PubMed ID: 11204323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in atypical degenerative dementias of the Alzheimer type.
    Wagner M; Teichner G; Bachman DL
    Arch Clin Neuropsychol; 2003 Dec; 18(8):893-903. PubMed ID: 14609583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease.
    Hashimoto R; Hirata Y; Asada T; Yamashita F; Nemoto K; Mori T; Moriguchi Y; Kunugi H; Arima K; Ohnishi T
    Genes Brain Behav; 2009 Feb; 8(1):43-52. PubMed ID: 18786162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].
    Shoji M
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1234-6. PubMed ID: 11464465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbleeds do not affect rate of cognitive decline in Alzheimer disease.
    van der Vlies AE; Goos JD; Barkhof F; Scheltens P; van der Flier WM
    Neurology; 2012 Aug; 79(8):763-9. PubMed ID: 22875093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease.
    Balasa M; Gelpi E; Antonell A; Rey MJ; Sánchez-Valle R; Molinuevo JL; Lladó A;
    Neurology; 2011 May; 76(20):1720-5. PubMed ID: 21576687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
    Anthony IC; Norrby KE; Dingwall T; Carnie FW; Millar T; Arango JC; Robertson R; Bell JE
    Brain; 2010 Dec; 133(Pt 12):3685-98. PubMed ID: 21126996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.